Efficacy of activating blood and resolving stasis therapy for IgA nephropathy:a systematic review and meta-analysis

Background:To systematically evaluate the efficacy and safety of activating blood and resolving stasis in patients with IgA nephropathy.Methods:From inception to May 2022,databases including PubMed,Embase,the Cochrane Library,Web of Science,WanFang database,Chinese Biomedical Database,VIP,and China National Knowledge Infrastructure were searched for randomized controlled trials about enhancing blood circulation and removing stasis for IgA nephropathy.For the articles that satisfied the requirements,quality assessment and meta-analysis were done.Results:Seventeen randomized controlled trials with a total of 1653 patients were included.Meta-analysis showed that activating blood and resolving stasis could increase therapeutic effectiveness(risk ratio(RR)=-0.47,95%confidence interval(CI)(-0.37,-0.2),P=0.0006)and decrease levels of serum creatinine(RR=-0.47,95%CI(-0.37,-0.2),P=0.0006),urea nitrogen(RR=0.85,95%CI(1.44,0.26),P=0.005),24-hour urinary protein quantification(RR=1.6,95%CI(2.44,0.95).P=0.00001),and urine red blood cell count(RR=1.7,95%CI(2.57,0.82),P=0.0001).There was no significant difference between the two groups in terms of security(RR=0.6,95%CI(0.36,1.01),P=0.05).Conclusion:Western medicine combined activating blood and resolving stasis is more efficient than Western medicine therapy alone in treating IgA nephropathy,but it still needs to be supported by additional large-scale,multi-center randomized controlled clinical trials due to the poor quality of the included trials.

Efficacy of the method of tonifying Qi,resolving phlegm and eliminating stasis in thetreatment of AECOPD:A meta analysis

Objective:To systematically evaluate the efficacy and safety of the method of tonifying qi,resolving phlegm and eliminating stasis in the treatment of acute exacerbation of chronic obstructive pulmonary disease.Methods:Search the China Knowledge Network(CNKI),VIP Chinese Science and Technology Journal Database(VIP),Wanfang Data Knowledge Service Platform,China Biomedical Literature Database(CBM),PubMed,Embase,Cochrane Library,and select the databases that meet the requirements for tonifying qi,resolving phlegm and eliminating stasis.The stasis method in the treatment of AECOPD was included in the standard literature,and RevMan 5.4 software was used for statistical analysis.Results:A total of 10 articles were included,with a total of 854 patients,435 in the treatment group and 419 in the control group.Systematic analysis shows that the method of tonifying qi,resolving phlegm and eliminating stasis combined with conventional Western medicine treatment of AECOPD is significantly different in total clinical effective rate than conventional Western medicine treatment alone[OR=3.98,95%CI(2.23,7.11),P<0.00001];In terms of lung function,FEV1/FVC[MD=6.08,95%CI(5.01,7.15),P<0.00001],FEV1[MD=0.07,95%CI(0.01,0.13),P=0.02],FEV1%[MD=4.56,95%CI(3.09,6.02),P<0.00001]is significantly higher than the control group;arterial oxygen partial pressure(PaO_(2))[MD=18.47,95%CI(16.77,20.16),P<0.00001]Significant improvement compared to the control group;arterial partial pressure of carbon dioxide(PaCO_(2))[MD=-7.48,95%CI(-8.7,-6.26),P<0.00001]was significantly lower than the control group.Conclusion:The current evidence shows that the method of tonifying qi,resolving phlegm and eliminating stasis combined with conventional Western medicine treatment of chronic obstructive pulmonary disease in acute exacerbations can improve clinical efficacy and improve the quality of life of patients.

Research Progress and Prospects on the Anti-liver Fibrosis,Blood Circulation-promoting and Stasis-resolving Effects of Curcuma kwangsiensis Based on W-P Bodies

Liver fibrosis is a necessary stage in the progression of chronic liver disease to cirrhosis.So far,no satisfactory drugs have been found to intervene in liver fibrosis.Liver microcirculation disorders are one of the important pathogenesis of chronic liver disease,and hepatic sinusoidal endothelial cells(HSECs)are the main cells that constitute the liver microcirculation barrier.In clinical practice,W-P bodies have been detected in HSECs of most patients with liver fibrosis.W-P bodies serve as a site for the synthesis and storage of vW factors,ET-1 and other cytokines that promote liver fibrosis.They can disrupt the structure and function of HSECs,cause liver microcirculation disorders,and exacerbate the progression of liver fibrosis.Previous studies have found that the Guangxi specialty ethnic medicine,C.kwangsiensis S.G.Lee et C.F.Liang,has definite effects in promoting blood circulation,resolving blood stasis,and resisting liver fibrosis.Based on this,a further research idea has been derived,stating that the blood circulation-promoting,blood stasis-resolving,and anti-liver fibrosis effects of C.kwangsiensis are produced by affecting the formation of W-P bodies,the synthesis and storage of contents in W-P bodies,and intervening in their exocytosis capacity.

Effects of Activating Blood Circulation to Resolve Blood Stasis and Glucosamine Capsules Therapy on the Expression of Matrix Metalloproteinase in Post-traumatic Knee Osteoarthritis

[Objectives] To observe the clinical effects of activating blood circulation to resolve blood stasis and glucosamine hydrochloride capsules therapy on post-traumatic knee osteoarthritis treatment,to measure the expression of matrix metalloproteinase in post-traumatic knee osteoarthritis patients before and after treatment,and to explore its relevant molecular mechanisms. [Methods]A total of 60 patients with posttraumatic knee osteoarthritis in early stage in Affiliated Hospital of Shannxi University of Chinese Medicine from January 2015 to December2017 were selected and randomly divided into the control group( n = 30) and the observation group( n = 30). The control group was given oral administration of glucosamine hydrochloride capsules for 6 courses of the treatment. The observation group was using the activating blood circulation to resolve blood stasis therapy for 6 courses of treatment. The recovery of traumatic knee osteoarthritis and the symptom of traditional Chinese medicine( TCM) in 2 groups was compared before and after treatment. The symptoms and the quantitative assessment rating scale of knee osteoarthritis,the pain index of knee and the TCM symptom scores were recorded in both groups. And the synovial fluid and serum of patients were collected to detect the expression of matrix metalloproteinase. [Results]The symptoms and the quantitative assessment rating scale of knee osteoarthritis,the pain index of knee and TCM symptom scores of the 2 groups in the 1 st week,the 12 th week and the 24 th week after the treatment were significantly lower than those before the treatment,and the difference was statistically significant( P < 0. 05). Two therapeutic methods had certain therapeutic effects on the recovery from traumatic knee osteoarthritis,and could significantly improve the TCM syndrome. There were better therapeutic effects on oral decoction of traditional Chinese medicine than oral glycosaminoglycans hydrochloride capsules on treating traumatic knee osteogenesis( P < 0. 05). The expression level of MMP3 was decreased significantly in both groups( P <0. 001),while the expression level of MMP13 had no significant change in both groups( P >0. 05). The expression level of MMP1 was decreased significantly in the observation group( P < 0. 001),but there was no significant change in the control group after treatment( P >0. 05). [Conclusions]Two treatment methods have been effective in this clinical study. We found that the expression level of MMP3 was decreased significantly after treatment in 2 therapies,which can be clinically applied.

益气活血、化痰通络法治疗煤工尘肺缓解期患者的临床研究

目的评价益气活血、化痰通络法治疗对煤工尘肺(CWP)缓解期患者呼吸困难、肺功能、生活质量等指标的改善情况。方法选取2020年10月—2022年9月北京中医药大学房山医院就诊的CWP缓解期患者80例,采用随机数字表法分为观察组与对照组。观察组给予西医常规治疗加益气活血、化痰通络颗粒,1剂/d,分早晚2次口服。对照组给予西医常规治疗加安慰剂,1剂/d,分早晚2次口服。2组疗程均4周,随访8周。对比2组呼吸困难疗效及安全性评价,治疗前后肺功能指标[第1秒用力呼气容积(FEV1)、用力肺活量(FVC)及FEV1/FVC]、6分钟步行距离、中医症状积分。结果治疗4周后,观察组总有效率86.8%,高于对照组的61.5%(P<0.05)。治疗第4周,观察组中医症状积分低于治疗前及对照组(P<0.05);观察组FVC高于治疗前(P<0.05)。治疗第4周、随访第4周,观察组6分钟步行距离均长于治疗前(P<0.05),第4周2组间差异有统计学意义(P<0.05)。在治疗及随访期间,2组患者均未发生不良事件。结论益气活血、化痰通络法联合西医治疗可降低CWP缓解期患者的呼吸困难程度,并对中医症状积分、FVC和6分钟步行距离有改善作用。

Pleiotropic Effects of Herbs Characterized with Blood-Activating and Stasis-Resolving Functions on Angiogenesis

Accumulative evidences have underpinned the nature candidates from Chinese medicine （CM）, particularly CM served as blood activating and stasis resolving （BASR, Huoxue Huayu in Chinese） by targeting tumor-associated angiogenesis. However, recent experiment research on the therapeutic angiogenesis by BASR-CM attracts wide attention and discussion. This opinion review focused on the underlying link between two indications and anticipated that （1） BASR-CM might emphasize on a balanced multi-cytokines network interaction; （2） BASR-CM might address on the nature of diseases prior to differently affecting physiological and pathological angiogenesis; （3） BASR-CM might mainly act on perivascular cells, either promotes arteriogenesis by increasing arteriogenic factors in ischemic diseases, or simultaneously keep a quiescent vasculature to impede angiogenesis in tumor context.

冯俊运用剔络化瘀法治疗RVO经验浅析

视网膜静脉阻塞(RVO)是由多种因素引起的视网膜静脉血栓形成从而产生一系列眼底病变,主要表现为视网膜血管迂曲扩张、火焰状出血,波及黄斑区引起黄斑水肿(ME),长期反复水肿则会导致视网膜光感受器细胞缺氧、坏死,不可逆损伤,是一种难治性、致盲性的眼病。西医治疗主要为视网膜激光、药物注射及外科手术等,常有复发者。冯俊教授对视网膜血管性疾病深入研究,认为目络瘀阻,血水不利,瘀血邪气阻络,络脉受损是RVO的基本病机,以络病理论和眼底气血理论为指导,自创剔络化瘀法,临证以剔络化瘀方进行加减,对于RVO引起的视网膜出血及反复ME,效果显著。

由Nrf2/GPX4调控铁死亡探讨从“瘀”论治激素性骨质疏松症

核转录因子-相关因子2(Nrf2)/谷胱甘肽过氧化物酶4(GPX4)作为胞内关键的抗氧化应激途径,保护多种骨形成相关细胞免受铁死亡的损害,是激素性骨质疏松症(glucocorticoid-induced osteoporosis,GIOP)发病的潜在机制。GIOP因瘀致痹的病机与该系统密切相关,从“瘀”论治的效应可通过该通路轴向调控的微观信息来表达;同时中医治疗GIOP时重视“瘀证”的辨证论治,且临床通常以活血化瘀类、益气活血类中药多见。因此,基于Nrf2/GPX4调控铁死亡探讨从“瘀”论治GIOP的科学性,以“瘀证”为理论指导明确活血化瘀类中药参与Nrf2/GPX4通路调控BMSCs、ECs、OB铁死亡来治疗GIOP,以期为从“瘀”论治GIOP提供科学理论依据,为深入理解GIOP病理生理及临床防治提供新的视角。

基于络病学说探讨动脉粥样硬化辨治规律

动脉粥样硬化属中医脉络病范畴,发生与发展与络病学说密切相关。基于络病学说,总结本病病机为本虚标实,其中本虚为脏腑功能受损,络虚不荣,标实为痰、瘀、毒互结,络阻不通,络道亢变、络道绌急、络久成积是本病病情进展的重要因素,治疗采用攻补兼施的原则,具体治法有益气养阴荣络、活血化痰通络和平衡阴阳宁络,以使气血充和,阴阳平衡,络脉条达。

祛瘀化痰中药复方对心房颤动大鼠线粒体自噬PINK1/Parkin通路作用机制研究

目的 观察祛瘀化痰中药复方对心房颤动大鼠心肌自噬影响及可能的作用机制。方法 将90只健康雄性大鼠随机分成正常组、模型组、胺碘酮组及中药低、中、高剂量组;除正常组外,各组大鼠进行尾静脉注射Ach-CaCl_(2)混合液制备心房颤动模型。电生理记录仪测量大鼠Ⅱ导联房颤持续时间,HE染色观察房颤大鼠心肌组织变化,Western blotting检测各组大鼠心肌组织PINK1、Parkin、LC3B、P62、Atg5和Beclin1蛋白表达情况。RT-PCR检测各组大鼠心肌组织PINK1、Parkin、LC3B和P62 mRNA表达情况。结果 与正常组相比,其余各组大鼠心电图均出现典型AF改变(P<0.01);模型组大鼠PINK1、Parkin、LC3B、Atg5、Beclin1蛋白及mRNA表达降低(P<0.01),P62蛋白及mRNA表达升高(P<0.01)。与模型组相比,中药低、中、高剂量组及胺碘酮组大鼠AF持续时间均缩短(P<0.05);PINK1、Parkin、LC3B、Atg5、Beclin1蛋白及m RNA表达升高(P<0.05),P62蛋白及mRNA表达降低(P<0.05)。结论 祛瘀化痰中药复方可以上调PINK1/Parkin通路,进一步激活线粒体自噬,减轻心肌的损伤,从而保护心肌组织,缓解房颤的发生并对房颤产生治疗作用。

余仁欢辨治药物性肾损害经验

药物性肾损害作为临床用药较为常见的不良反应事件,在治疗上具有一定难度。余仁欢教授认为治疗药物性肾损害应重点关注损伤程度、损伤部位、急慢性质以及患者素体情况等。对于平素体健猝逢药毒攻伐的实证患者,以解毒泻浊化瘀法治之;对于脾肾虚甚、不耐药之毒性或偏性的虚证患者,以补脾益肾法治之;对于脾肾素亏又逢药毒攻伐致脾肾两虚、痰凝湿阻、络损血瘀的虚实夹杂证患者,以健脾祛湿、化瘀和络法治之。附验案1则。

某院2012~2022年中药注射剂不良反应分析

目的研究某院中药注射剂不良反应发生的特点及规律,为中药注射剂临床合理应用提供参考依据,尽可能减少中药注射剂致不良反应的发生概率。方法从国家不良反应监测系统中导出某院2012~2022年度中药注射剂相关不良反应171例,利用Excel软件整理归类并分析。结果171例中药注射剂相关不良反应中,男女比例为1∶1.67;年龄41~60岁区间占据比例最大;21种中药注射剂发生不良反应,活血化瘀类发生不良反应的病例数占比达70.76%,其中注射用血塞通发生不良反应例数最多;用药后超过7 d发生不良反应的例数最多,占比42.69%;过敏反应以皮疹瘙痒最常见;6例存在联合应用两种中药注射剂的现象。结论中药注射剂不良反应的发生与多种因素有关,通过整理某院中药注射剂不良反应的发生特点,提醒医护人员在临床用药过程中要足够重视,临床药师要加强药学监护,共同协作,关注用药过程中每一环节,促进临床用药的合理性和安全性。

基于络病理论与“主客交”学说探讨黑棘皮症病机演变与治疗方法

络病理论与“主客交”学说相互贯通,二者均与血脉密切相关。黑棘皮症的皮损症状是由血络与气络瘀阻不通导致,也是“主客交”的一种持续状态。文章基于络病理论与“主客交”学说,阐述黑棘皮症“因虚感邪、邪入于络、络脉瘀阻、络瘀成毒”的病机演变过程,并据这一过程提出黑棘皮症的治疗方法,即补虚以通络、化瘀以畅络、解毒以活络,以期为中医辨治黑棘皮症提供新思路。

Treatment of Posthepatitic Cirrhosis by Fuzheng Huayu Tablet(扶正化瘀片) for Reinforcing Qi and Resolving Stasis

Objective： To investigate the efficacy and safety of the Fuzheng Huayu Tablet （扶正化瘀片, FZHYT）, which is used to reinforce qi and resolve stasis in patients with posthepatitic cirrhosis （PHC）. Methods： A multicenter, randomized, controlled clinical trial was conducted in 180 patients with PHC. The patients were randomly assigned using random numbers to a treatment group treated with FZHYT and a placebo group; the treatment course was 6 months for both groups. Overall response, adverse events （AEs）, and the 2-year survival rate were assessed after treatment. Evaluations were made on changes in liver function, liver fibrosis, coagulation, hemodynamics, degrees of esophagogastric varices, ascites, quality of life （QOL）, and scores of main symptoms. Results： The overall response was significantly higher in the treatment group than the placebo group （86.7% vs. 62.2%, P〈0.01）. Patients in both groups had significant improvements in liver function [total bilirubin （TBIL）, albumin （ALB）], liver fibrosis [hyaluronic acid （HA）, type 1V collagen （CIV）], coagulation [prothrombin time （PT）, activated partial thromboplastin time （APTT）, fibrinogen （FIB）, and thrombin time （TT）], hemodynamics portal venous flow （PVF）, and splenic vein flow （SVF） after treatment. Between-group comparisons showed that compared with the placebo group patients in the treatment group achieved significantly greater improvements in TBIL, ALB, HA, C IV, PT, AP＇I-r, PVF, SVF, time to ascites resolution, 2-year survival, QOL, and symptom scores （P〈0.05 or P〈0.01）. There were no significant AEs during the treatment. Conclusion： FZHYT is effective and safe for the treatment of hepatic cirrhosis as it is associated with improved liver function, liver fibrosis, coagulation, portal hypertension state, QOL, 2-year survival rate, and fewer AEs.

中华跌打丸活血化瘀作用的实验研究

目的:观察中华跌打丸对大鼠急性血瘀模型的体外血栓形成、血液黏度、血小板聚集率和对小鼠微循环障碍模型耳郭微循环的影响,评价中华跌打丸活血化瘀的作用。方法:通过注射肾上腺素加冰水刺激的方法建立大鼠急性血瘀模型,测定体外血栓形成和血液黏度;按照Born氏比浊法加入诱导剂诱导聚集测定大鼠血小板聚集率;尾静脉注射15%高分子右旋糖酐造成微循环障碍,观察小鼠耳郭各时段微动脉和微静脉管血液流速和血管管径的变化。结果:中华跌打丸可降低血瘀模型大鼠的血液黏度,在切变率150 S^(-1)、60 S^(-1)及5 S^(-1)下的全血黏度均显著降低(P<0.05),明显缩短血瘀模型大鼠血栓长度,减轻血栓湿重和干重(P<0.05,P<0.01);中华跌打丸具有抑制血小板聚集的作用,各剂量均能明显降低ADP诱导的大鼠血小板聚集率(P<0.05,P<0.01);中华跌打丸对高分子右旋糖酐所致小鼠耳郭微循环障碍有明显改善作用,于造模10 min、20 min、30 min时增加血液流速(P<0.05,P<0.01),扩大微动脉、微静脉管径(P<0.05,P<0.01),减轻红细胞聚集(P<0.05,P<0.01)。结论:中华跌打丸可明显改善血液黏度,抑制血小板聚集,改善微循环障碍,有较好的活血化瘀作用。

益气养阴化痰祛瘀法对甲状腺机能亢进症激素抗体及氧化应激因子表达的影响

目的研究益气养阴化痰祛瘀法对甲状腺机能亢进症(Hyperthyroidism,简称甲亢)患者激素抗体和氧化应激因子表达的影响。方法选取2022年1月—2023年12月收治的76例甲亢患者,按照随机数字表法分组,对照组(38例)采用常规西药治疗,观察组(38例)在对照组基础上加用益气养阴化痰祛瘀方治疗;治疗2个月后对比两组临床疗效、中医证候积分、甲状腺功能(各项激素水平)、氧化应激因子、促甲状腺激素受体抗体(TRAb)、甲状腺过氧化物酶抗体(TPOAb)的表达。结果观察组治疗总有效率为94.74%(36/38),高于对照组(76.32%,29/38),差异有统计学意义(P<0.05)。治疗后,两组主症积分、次症积分和舌脉积分均降低,观察组低于对照组;两组促甲状腺激素(TSH)上升,游离三碘甲状腺原氨酸(FT3)、游离甲状腺素(FT4)下降(P<0.05),观察组改善高于对照组;两组超氧化物歧化酶(SOD)升高,观察组SOD水平高于对照组,差异有统计学意义(P<0.05)。结论益气养阴化痰祛瘀法用于甲亢患者的治疗取得确切治疗成果,可以有效改善甲状腺功能,通过调控甲状腺激素水平、TRAb、TPOAb以及氧化应激因子的表达以改善病情,缓解症状。

除湿化瘀汤内服外用治疗慢性前列腺炎湿热瘀滞型临床研究

目的:观察除湿化瘀汤内服外用治疗慢性前列腺炎湿热瘀滞型的疗效。方法:108例随机分为联合治疗组、单纯中药组及成药对照组各36例,联合治疗组用除湿化瘀汤熏蒸加内服,单纯中药组用除湿化瘀汤内服,成药对照组给予前列舒通胶囊。结果:总有效率联合治疗组91.67%(33/36),单纯中药组69.44%(25/36),成药对照组72.22%(26/36),3组比较差异有统计学意义(P<0.05)。3组治疗后各项评分均降低(P<0.05),联合治疗组评分更低(P<0.05),单纯中药组治疗后与成药对照组比较差异无统计学意义(P>0.05)。3组最大尿流率与平均尿流率均提升,联合治疗组较单纯中药组及成药对照组升幅更大(P<0.05)。结论:中药内服联合熏蒸治疗慢性前列腺炎湿热瘀滞型效果较好。

王阶从“虚-痰-瘀-热-滞”论治冠状动脉狭窄经验

冠状动脉粥样硬化斑块导致冠状动脉狭窄是冠心病发病的关键和病理基础。目前,冠心病的常规治疗措施包括药物治疗和血运重建,在一定程度上能改善症状,但仍有发生不良心血管事件的风险。全国名中医王阶教授临证经验丰富,在中医辨治冠心病及用药方面独具特色。王教授提出,冠心病的核心病机是“痰瘀滞虚”,四大证候要素紧密结合,互相转化,贯穿于冠心病发生、发展的全过程。王教授认为,冠状动脉狭窄与“虚、痰、瘀、热、滞”病机密切相关,其中“虚”为内在致病之本,“血瘀、痰浊”是主要病理因素,“热毒内蕴”是重要病机,“气滞”是加重病情、干扰疾病转归的重要因素。王教授临证时强调治病求本,病机结合病理,脏腑辨证和病证结合,方证相应指导处方用药,药性结合药理,灵活配伍。治疗上,以益气补肾、活血化痰、清热解毒之法立法组方,擅用经方加减化裁,守机用之,遵旨变通;或合方治疗,兼顾病情;善用对药配伍,强化药效,颇具特色。现将王阶教授在冠状动脉狭窄治疗方面的临床经验总结如下,并附医案一则,以飨同道。

冯俊运用剔络化瘀法治疗视网膜血管瘤样增生经验

视网膜血管瘤样增生(RAP)属于湿性年龄相关性黄斑变性的一种特殊类型,其基本病变为新生血管形成。临床上往往采取对症治疗,但预后较差。冯俊深入研究古代医家的相关论述,结合多年临床应用经验,基于中医“络病理论”思想,阐述了络病与RAP的内在联系,提出了RAP属中医络病,认为“瘀阻脉络、水湿内停”为其主要病机,在治疗上采用剔络化瘀法,即应用虫类药与活血化瘀药物搜剔络脉、活血化瘀,兼顾利水渗湿,并调补全身气血,畅通眼底络脉,从而达到充养目系、固本明目之效。在其临床实践中该法疗效显著,为临床治疗RAP提供了新方法、新思路。

活血化瘀药对不稳定型心绞痛患者PAI-1、t-PA影响的Meta分析

目的探讨活血化瘀药对不稳定型心绞痛(Unstable angina,UA)患者纤溶酶原激活物抑制物(Plasminogen activator inhibitor-1,PAI-1)、组织型纤溶酶原激活剂(Tissue-type plasminogen activator,t-PA)水平的影响,进而评价活血化瘀药对不稳定型心绞痛患者临床疗效,从而为临床预防治疗不稳定型心绞痛提供依据。方法通过检索PubMed、EMbase、The Cochrane Library、Web of Science、ClinicalTrials.gov、万方数据和中国知网数据库,收集活血化瘀药联合西医常规治疗UA的随机对照试验(RCT)文献,采用RevMan 5.4软件进行Meta分析。结果共纳入22项研究,涉及1998例研究对象。Meta分析结果显示,与西药相比,联用活血化瘀中药可以进一步降低UA患者血清PAI-1水平[SMD=-1.96,95%CI(-2.50,-1.43)],Z=7.18,P<0.00001,升高UA患者t-PA水平[SMD=0.55,95%CI(0.41,0.69)],Z=7.85,P<0.00001。结论与常规西药治疗相比,联用活血化瘀药可进一步降低UA患者体内PAI-1水平、升高t-PA水平,改善患者纤溶活性。